Veracyte reported $1.57B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
Agilent USD 13.97B 902M Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 1.74B 373.76M Sep/2026
Bruker USD 5.83B 224.6M Sep/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Illumina USD 6.81B 162M Sep/2026
Intrexon USD 73.16M 77.88M Jun/2024
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Laboratory Of America USD 18.92B 392.3M Sep/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Siemens EUR 169.87B 2.32B Sep/2026
Sonic Healthcare AUD 15.38B 550.57M Dec/2024
Thermo Fisher Scientific USD 114.23B 1.06B Sep/2026
Veracyte USD 1.57B 86.89M Sep/2026
Waters USD 24.12B 636M Sep/2026